Home » Topics » BioWorld Science

BioWorld Science
RSS

CStone Pharmaceuticals announces dosing of first patient in phase III GEMSTONE-303 study

April 16, 2019

MediciNova moves forward with a phase III study of MN-166 in ALS

April 16, 2019

Diamyd Medical presents 30-month results from phase IIa EDCR study

April 16, 2019

FDA gives clearance to initiate phase II/III study of ARO-AAT for AATD liver disease

April 16, 2019

Hansa receives ethics and regulatory clearance to initiate phase II study of imlifidase in GBS

April 16, 2019

Shenyang Pharmaceutical University patents neuraminidase inhibitors

April 16, 2019

RTI-1092663 improves metabolic syndrome in mice

April 16, 2019

S100B SNPs and haplotypes as markers of acute and chronic pain in sickle cell disease

April 16, 2019

Preclinical characterization of PF-06882961

April 16, 2019

Synapse formation important for ketamine durability

April 16, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Fauci’s silence may put him in contempt of Congress
BioWorld
After repeatedly invoking the Fifth Amendment to every question asked during the July 29 hearing of the U.S. Senate Homeland Security Committee, Anthony Fauci,...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...